Eli Lilly pulls sepsis drug Xigris off all markets, due to lack of efficacy


US drug major Eli Lilly (NYSE: LLY) revealed yesterday that it is withdrawing its Xigris (drotrecogin…

Antibiotics and Infectious diseasesEli LillyMarkets & MarketingPharmaceuticalResearchXigris

Eli Lilly forms JV BioCritica, to focus on sepsis drug Xigris


US drug major Eli Lilly (NYSE: LLY) has signed agreements with private investors Care Capital and NovaQuest…

Antibiotics and Infectious diseasesBioCriticaEli LillyLicensingMergers & AcquisitionsPharmaceuticalXigris

Back to top